Clinical trials: Neoplasms, Germ Cell and Embryonal
Uveal Melanoma
Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma
The objectives of the study are the morpho-phenotypic evaluation of uveal melanoma and to identify molecular prognostic factors that may be correlated with disease severity, tumour progression and response to treatment.
- Trial name
- MicroGenUM (NCT05889481)
- Testing
- cytogenetic analysis on tumour tissue, Digital Pathology
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival.
- Trial name
- NCT07091864
- Testing
- Best Practice, Biospecimen Collection, Dietary Intervention
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- Mayo Clinic
Astrocytoma, Grade IV
ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma.
- Trial name
- ALBATROSS (NCT05229198)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Juan M Garcia-Gomez
Glioma, Neurofibromatosis Type 1
MicroRNAs in Patients With Neurofibromatosis Type 1
MicroRNAs are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer.
- Trial name
- NCT01595139
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients…
- Trial name
- NCT07143812
- Testing
- MSC11FCD
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHA University
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Vestibular Schwannoma, Hearing Loss
Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot Study
Patients undergoing cochlear implantation after radio surgery for vestibular schwannoma will be included in the study. Patients will undergo preoperative and intraoperative eABR measurement.
- Trial name
- NCT03745534
- Testing
- eABR
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Christoph Arnoldner
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Advanced/Metastatic Neuroendocrine Tumors
Pazopanib as Single Agent in Advanced NETs
The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R.
- Trial name
- NCT01280201
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238277
- Testing
- temozolomide, adjuvant therapy, chemotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Immune-Related Adverse Events
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
The goal of this clinical trial is to investigate the safety of rituximab for management of immune-related adverse events in malignant melanoma patients.
- Trial name
- RiTOX (NCT07694414)
- Testing
- Rituximab (RTX)
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Inge Marie Svane
Glioblastoma (GBM)
Effect of stRess and exeRcize on the Outcome After Chemo-Radiation
Glioblastoma (GBM) is a highly malignant, incurable primary brain tumor. Due to the nature of this disease and the extent of the treatment (surgery followed by chemoradiation according to the Stupp trial) patients undergo…
- Trial name
- ERROR (NCT05431348)
- Testing
- Smartwatch, Serum Cortisol, Questionnaires
- Where
- 2 sites in Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht Radiation Oncology
Melanoma
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
To determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
- Trial name
- NCT06683755
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma.
- Trial name
- NCT07516678
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
A Study of NST-628 in Recurrent Grade 4 Glioma
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression…
- Trial name
- NCT07784985
- Testing
- NST-628
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nader Sanai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.